header logo image


Page 20«..10..19202122..3040..»

Archive for the ‘Personalized Medicine’ Category

Global Microbiome Sequencing Market 2020 Business Outlook with Pandemic Scenario Analysis and Forecast 2026|Oxford Nanopore Technologies; BaseClear…

Saturday, July 11th, 2020

Global microbiome sequencing marketis expected to rise to an estimated value of USD 3455.33 million by 2026, registering a healthy CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the focus of various researchers on utilization of this technology in the development of personalized medicine and dietary applications.

The study of Microbiome Sequencing report helps businesses to define their own strategies about the development in the existing product, modifications to consider for the future product, sales, marketing, promotion and distribution of the product in the existing and the new market. The research and analysis performed in this report with the consistent knowledge gives businesses clear idea of what is already available, what the market expects, the competitive environment, and what can be done to outshine the competitor. This research study also helps businesses to understand the various drivers and restraints impacting the market during the forecast period.

Ask For Complimentary Sample PDF| Request Athttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-microbiome-sequencing-market

Few of the major competitors currently working in the global microbiome sequencing market areBIOLOG; Cosmosid Inc; Illumina, Inc.; Metabiomics Corp.; Oxford Nanopore Technologies; BaseClear B.V.; BGI; BioMathematica; Charles River; CoreBiome, Inc.; Clinical-Microbiomics A/S; Diversigen; Eurofins Scientific; LABCYTE INC.; Leucine Rich Bio Pvt Ltd.; Microbiome Insights; MICROBIOME THERAPEUTICS, LLC; Thermo Fisher Scientific Inc.; Molzym GmbH & Co. KG; Norgen Biotek Corp.; Phase Genomics Inc.; QIAGEN; Resphera Biosciences, LLC; Shoreline Biome; StarSEQ GmbH; Viome, Inc.; Zymo Research among others.

Key Insights in the report:

Key Developments in the Market:

Access Complete Report @ https://www.databridgemarketresearch.com/reports/global-microbiome-sequencing-market

Market Drivers

Market Restraints

Segmentation: Global Microbiome Sequencing Market

By Sequencing Technology

By Component

By Targeted Disease

By Application

By Research Type

By End-User

By Laboratory Type

ByGeography

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-microbiome-sequencing-market

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like Asia, United States, and Europe.Contact:Data Bridge Market ResearchTel: +1-888-387-2818Email:[emailprotected]

Read more:
Global Microbiome Sequencing Market 2020 Business Outlook with Pandemic Scenario Analysis and Forecast 2026|Oxford Nanopore Technologies; BaseClear...

Read More...

Personalized Medicine Market Growth By Manufacturers, Countries, Types And Application, End Users And Forecast To 2026 – 3rd Watch News

Saturday, July 11th, 2020

New Jersey, United States,- Verified Market Research sheds light on the market scope, potential, and performance perspective of the Personalized Medicine Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the Personalized Medicine market.

The research study includes the latest updates about the COVID-19 impact on the Personalized Medicine sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Personalized Medicine manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Industrial Analysis:

The Personalized Medicine market report is extensively categorized into different product types and applications. The study has a separate section for explaining the cost of raw material and the revenue returns that are gained by the players of the market.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Personalized Medicine sector and can help companies in deciphering the optimum business move to reach their desired business goals.

In Market Segmentation by Types of Personalized Medicine, the report covers-

Bytype1

In Market Segmentation by Applications of the Personalized Medicine, the report covers the following uses-

Byapplication1

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=3WN&utm_medium=002

The Personalized Medicine market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Personalized Medicine market.

This study analyzes the growth of Personalized Medicine based on the present, past and futuristic data and will render complete information about the Personalized Medicine industry to the market-leading industry players that will guide the direction of the Personalized Medicine market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Personalized Medicine market. Additionally, it includes a share of each segment of the Personalized Medicine market, giving methodical information about types and applications of the market.

Reasons for Buying Personalized Medicine Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Personalized Medicine market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=3WN&utm_medium=002

In the end, the Personalized Medicine market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the Personalized Medicine market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Read the original:
Personalized Medicine Market Growth By Manufacturers, Countries, Types And Application, End Users And Forecast To 2026 - 3rd Watch News

Read More...

Impact of COVID-19 on Personalized Medicines 2020 Industry Growth, Size, Trends, Share, Opportunities and Forecast to 2026 – Jewish Life News

Saturday, July 11th, 2020

It is our aim to provide our readers with report for Personalized Medicines Market, which examines the industry during the period 2020 2026. One goal is to present deeper insight into this line of business in this document. The first part of the report focuses on providing the industry definition for the product or service under focus in the Personalized Medicines Market report. Next, the document will study the factors responsible for hindering and enhancing growth in the industry. After covering various areas of interest in the industry, the report aims to provide how the Personalized Medicines Market will grow during the forecast period.

The major vendors covered:

3G Biotech, Quest Diagnostics, Laboratory Corporation of America, Abbott, Agendia NV, Asuragen Inc, Becton Dickinson, CardioDx Inc., Foundation Medicine, Qiagen, Siemens Healthcare, Amgen, Bristol-Myers Squibb, GE Healthcare, Pfizer, Sanofi, 23andMe, Illumina. and more

The final report will add the analysis of the Impact of Covid-19 on Personalized Medicines Market.

Request a free sample copy @ https://www.reportsandmarkets.com/sample-request/global-personalized-medicines-market-report-2020?utm_source=jewishlifenews&utm_medium=38

The Personalized Medicines Market report between the years 2020 2026 will highlight the current value of the industry. At the same time, there is also an estimate of how much this line of business will be worth at the end of the forecast period. As it is our goal to maintain high levels of accuracy at all times, we will take a look at the CAGR of the Personalized Medicines Market. We make sure that all the information available in this report has excellent levels of readability. One way we achieve this target is by Personalized Medicines Market segmentation. Going through the report for 2020 2026 will bring our readers up-to-date regarding this industry.

While examining the information from this document, one thing becomes clear, the elements which contribute to increase in demand for the product or service. At the same time, there will be a focus on what drives the popularity of these types of products or services. This report is for those who want to learn about Personalized Medicines Market, along with its forecast for 2020 2026. Information regarding market revenue, competitive partners, and key players will also be available.

Segmentation

As discussed earlier, there is segmentation in the Personalized Medicines Market report, to improve the accuracy and make it easier to collect data. The categories which are the dividing factors in the industry are distribution channels, application, and product or service type. With this level of segmentation, it becomes easier to analyze and understand the Personalized Medicines Market. At the same time, there is emphasis on which type of consumers become the customers in this industry. When it comes to distribution channels, the Personalized Medicines Market report looks at the different techniques of circulation of the product or service.

Regional Overview

In this part of the Personalized Medicines Market report, we will be taking a look at the geographical areas and the role they play in contributing to the growth of this line of business. The areas of interest in this document are as follows Middle East and Africa, South and North America, Europe, and Asia Pacific. From the Personalized Medicines Market report, it becomes clear which region is the largest contributor.

Latest Industry News

From this Personalized Medicines Market report, the reader will also get to learn about the latest developments in the industry. The reason is that these products or services have the potential to disrupt this line of business. If there is information about company acquisitions or mergers, this information will also be available in this portion of the Personalized Medicines Market report.

If you have any special requirements about this Personalized Medicines Market report, please let us know and we can provide custom report.

Inquire more about this report @ https://www.reportsandmarkets.com/enquiry/global-personalized-medicines-market-report-2020?utm_source=jewishlifenews&utm_medium=38

About Us

ReportsAndMarkets.com allocates the globally available market research and many company reports from reputed market research companies that are a pioneer in their respective domains. We are completely an autonomous group and serve our clients by offering the trustworthy available research stuff, as we know this is an essential aspect of Market Research.

Contact Us

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

See the rest here:
Impact of COVID-19 on Personalized Medicines 2020 Industry Growth, Size, Trends, Share, Opportunities and Forecast to 2026 - Jewish Life News

Read More...

COVID-19 Impact on Precision Medicine Industry 2020: Global Market Size, Emerging Trends, Business Growth, SWOT Analysis by Top Manufacturers, Demand…

Saturday, July 11th, 2020

TheGlobal Precision Medicine Marketis estimated to grow at a CAGR of XX% by 2025. This report features the market growth analysis and forecasting for the growth and revenue up to 2025 allied with the Precision Medicine market.

Get Sample Copy of this Report at https://www.orianresearch.com/request-sample/559884

The market size estimations have been provided in terms of value (USD million). The global Precision Medicine industry report also identifies major market players and provides analysis in terms of company overview, Financials, products & services, market trends, recent developments and growth strategies.

Precision Medicine Market2019 Industry Research Report provides important statistics, analytical and comparative data to give a complete understanding of the market Share, Size, Growth, Rising Trends and Cost Structure analysis.

This report offers in-depth information obtained through extensive primary and secondary research methods. The information has been further assessed using various effective analytical tools.

The report puts special emphasis on the most important details of the Global Precision Medicine Market Report 2019 market, filtered out with the help of industry-best analytical methods

Regionally, North America, Latin America, Europe, Asia Pacific, And The Middle East & Africa constitute the key market segments.

Top Key Players Analyzed in Global Precision Medicine Marketare

Complete report on Precision Medicine Industry spread across 122 pages, profiling 10 companies and supported with tables and figures. For more details Enquire @https://www.orianresearch.com/enquiry-before-buying/559884

Key Benefit Of This Report:

Target Audience:

Get Direct Copy of this Report @https://www.orianresearch.com/checkout/559884

Major Points Covered in Table of Contents:

7 Global Precision Medicine Market By Product Type

8 Global Precision Medicine Market By Applications

9 Global Precision Medicine Market By Region

Customization Service of the Report:

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities

About UsOrian Researchis one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Continue reading here:
COVID-19 Impact on Precision Medicine Industry 2020: Global Market Size, Emerging Trends, Business Growth, SWOT Analysis by Top Manufacturers, Demand...

Read More...

What Are Precision Medicine and Personalized Medicine?

Saturday, July 11th, 2020

January 11, 2018 -Since the beginning of recorded history, healthcare practitioners have striven to make their actions more effective for their patients by experimenting with different treatments, observing and sharing their results, and improving upon the efforts of previous generations.

Becoming more accurate, precise, proactive, and impactful for each individual that comes under their care has always been the goal of all clinicians, no matter how basic the tools at their disposal.

But now, modern physicians and scientists are now able to take this mission far, far beyond the reach of their ancestors with the help of electronic health records, genetic testing, big data analytics, and supercomputing all the ingredients required to engage in what is quickly becoming truly precise and personalized medicine.

Precision medicine, also commonly referred to as personalized medicine, is one of the most promising approaches to tackling diseases that have thus far eluded effective treatments or cures. Cancer, neurodegenerative diseases, and rare genetic conditions take an enormous toll on individuals, families and societies as a whole.

Approximately 1.7 million new cancer cases were diagnosed in the United States in 2017. Around 600,000 deaths were expected during that year, according to the American Cancer Society. The Agency for Healthcare Research and Quality adds that the direct economic impact of cancer is around $80 billion per year loss of productivity, wages, and caregiver needs sap billions more from the economy.

Many of these cancers are preventable through lifestyle changes, such as quitting tobacco, improving weight and diet, or reducing alcohol consumption, but many are also the result of predispositions to certain diseases inherited along ethnic, racial, or familial lines.

Neurological diseases, including Alzheimers disease, produce similarly dire impacts. Alzheimers is the 6th leading cause of death in the United States, and the Alzheimers Association predicts that 16 million individuals will be living with the disease by 2050.

Alzheimers and other forms of dementia cost the US approximately $259 billion in 2017. As the population ages and dementia cases increase in number, those costs will top $1.1 trillion by 2050.

The financial, clinical, and social imperatives for finding cures for these and other conditions have led to a surge in interest around precision medicine. With much more digital data at their disposal and the computing power to crunch the numbers, researchers are now eagerly uncovering new relationships between genes, drugs, and populations.

Fully unlocking the secrets of how an individuals genetics impacts his or her likelihood of developing or surviving a particular condition would produce a fundamental revolution in the way providers approach the practice of medicine, moving the profession an incalculable distance from the basic experimentation of its prehistorical origins.

According to the Precision Medicine Initiative, precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.

Physicians have, of course, tailored their recommendations to individual factors such as age and gender, patient preferences, mobility levels, community resources, preexisting conditions, and other mitigating circumstances for many, many years.

The difference between a traditional shrewd assessment of a complex situation and true precision medicine is the degree of reliance on data especially genomic data to make decisions about specific treatment paths that may be more or less effective for the individual at hand.

Genomic data is a relatively new addition to the physicians toolkit, and researchers have barely begun to scratch the surface of what revolutionary insights are likely hidden in the human genetic code.

Genetic testing is getting quicker and cheaper, offering researchers the opportunity to collect larger volumes of data from more diverse patient groups.

By combining this data with clinical, pharmaceutical, and socioeconomic information, and then applying analytics to these integrated datasets, researchers and providers can observe patterns in the effectiveness of particular treatments and identify the genetic variations that may be correlated with success or failure.

Clinical trials can then be used to test and validate these hypotheses. If the results meet rigorous scientific standards, they may support future best practices or clinical guidelines for the treatment of specific conditions integrated into advanced clinical decision support systems.

Many stakeholders are starting to prefer the term precision medicine instead of personalized medicine to describe the use of data and genomics to tailor treatments to specific groups.

The National Research Council (NRC) has expressed concern that personalized medicine may be misconstrued to mean that completely individualized treatments are available for every unique patient, which is not the case.

In its 2011 report Towards Precision Medicine, the NRC states:

Precision medicine refers to the tailoring of medical treatment to the individual characteristics of each patient. It does not literally mean the creation of drugs or medical devices that are unique to a patient, but rather the ability to classify individuals into subpopulations that differ in their susceptibility to a particular diseaseor in their response to a specific treatment. Although the term personalized medicine is also used to convey this meaning, that term is sometimes misinterpreted as implying that unique treatments can be designed for each individual. It should be emphasized that in precision medicine, the word precision is being used in a colloquial sense, to mean both accurate and precise.

Personalized medicine has been falling out of favor since 2015, when President Barack Obama introduced the national Precision Medicine Initiative in his State of the Union speech, explained Muin J. Khoury, Director, Office of Public Health Genomics, Centers for Disease Control and Prevention, in a 2016 blog post.

Source: CDC

Precision medicine has overtaken personalized medicine as the preferred search term online, and the number of academic journal articles using precision instead of personalized has exploded.

The difference in search popularity is even more marked at the beginning of 2018, with precision medicine firmly the favorite among Google users in the United States.

The growing popularity of precision medicine over personalized medicine may be a good thing, Khoury said, as targeted therapies become more deeply integrated into everyday clinical care, requiring patient education and tempered expectations.

Source: Xtelligent Media

To be sure, precision medicine and personalized medicine are highly related and genomics plays a big role in both, said Khoury. However, even highly personalized information may or may not lead to improved health outcomes. Moreover, precision medicine approaches may lead to non-personalized interventions that can be used population-wide.

Direct-to-consumer (DTC) genetic testing kits, such as those offered by 23andMe or AncestryDNA, are an example of the divide between personalization and precision, he continued.

These commercial products can deliver very personalized information, but may not be particularly precise or actionable when it comes to an individuals health status or chances of developing specific conditions.

In many ways, DTC genetic tests are the opposite of precision medicine, observed Khoury. In spite of their deceptive appeal, they deliver uncertain information and create patient expectations that may align poorly with evidence; clinical priorities; or, in some cases, the patients best interests.

Using precision medicine instead of personalized medicine as the latter continues to slide out of favor may help to ensure clarity for patients who are interested in learning more about tailored care.

Interest in Genetic Testing Brings Precision Medicine Challenges

Artificial Intelligence, Genomics Combo Boosts Precision Medicine

Many of the scientific terms used to describe the progress and challenges of precision medicine require highly specialized knowledge to fully understand, which can be an obstacle for providers who wish to educate patients about precision medicine, its opportunities, and its limitations.

While most people are familiar with the concept of DNA and its basic role in many diseases, painting a fuller picture of how and why targeted therapies work may involve providing explanations of several of the following terms.

Genomics

The genome is an organisms complete set of genetic material. DNA includes coding regions, or genes, that govern the function of proteins, as well as non-coding sequences that perform regulatory functions. Genomics is the study of these materials.

Genetics

A gene is a subset of the genome that codes for a molecule that has a specific function, such as governing a persons eye color, blood type, or predisposition for certain diseases. Genes can acquire mutations when passed along through families, resulting in inherited conditions. Variations in an individuals phenotype, or the sum of its observable physical or behavioral characteristics, are due part to how individual genes combine to produce those traits.

Researchers are still discovering incredibly complex relationships between genes and diseases. The rapid advance of genetic research in the early years of the 21st century has been supported by initiatives like the Human Genome Project, which produced a composite genetic sequence that is freely available to the public. Scientists can compare cancer cells, for example, with this data to understand where and how specific mutations occur and what their impacts might be.

Genetic sequencing

Genetic sequencing, or DNA sequencing, is the process of determining the order of the four chemical building blocks of DNA (adenine, guanine, cytosine, and thymine) for an individual organism. The order of these chemicals in each strand of DNA dictates the type of genetic information included in a segment of DNA.

Researchers can identify which sections of a DNA molecule contain genes and which include regulatory information, allowing them to pinpoint differences between individuals with certain traits and those without. The human genome contains around 3 billion pairs of the four chemical bases of DNA, which all together provide the instruction manual for a living organism.

Source: National Institutes of Health

Since its start in the early 1970s, genetic sequencing has become so quick and inexpensive that healthcare providers can routinely order genetic testing for patients suspected of having conditions with a genetic component.

The falling prices and rising speed of these tests has been a significant catalyst for precision medicine. Interest in genetic testing has skyrocketed in recent years, with 90 percent of patients in one recent survey expressing some level of curiosity about receiving a genetic test.

Next-generation sequencing

Next-generation (next-gen) sequencing is a collection of techniques that have further enhanced the speed and detail of genetic sequencing.

Instead of sequencing an individuals entire genetic code from scratch every time, next-gen techniques sequence fragments of an individuals DNA, called reads, and then use algorithms to compare the results to a DNA library to fill in the gaps. Any differences or mutations can be identified during the process.

Next-gen sequencing allows laboratories to complete the process more quickly, helping to meet the growing demand for their services. The techniques are being developed and refined very rapidly as life science companies rush to provide researchers and healthcare organizations with one of the essential tools for precision care.

CRISPR

CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats), are part of an organisms bacterial defense system, first discovered by Francisco Mojica, a scientist at the University of Alicante in Spain.

They consist of repeating sequences of genetic code, interrupted by spacer sequences remnants of genetic code from past invaders. The system serves as a genetic memory that helps the cell detect and destroy invaders (called bacteriophage) when they return, says the Broad Institute.

CRISPRs form the basis for CRISPR-Cas9, a gene editing technology that allows researchers to target specific stretches of genetic code and alter the DNA within them.

This futuristic capability may allow scientists to correct damaging mutations or susceptibilities to diseases in living organisms without side effects from traditional pharmaceutical therapies and even rectify genetic conditions for which no pharmaceutical option exists.

Pharmacogenetics

Pharmacogenetics is the study of how genetic differences influence the metabolic pathways of drugs, or how individuals respond to specific pharmaceutical interventions based on their unique genetic makeup. This science forms the basis of many precision medicine efforts, such as choosing individualized drug combinations to attack a specific type of cancer.

For example, the drug Tamoxifen is widely used to treat breast cancer or prevent a recurrence, but up to 10 percent of individuals have a version of a gene that results in resistance to its positive effects.

Before prescribing the drug, providers can order a genetic test to see whether the individual has a genetic makeup that would reduce the effectiveness of the drug.

Pharmacogenetics (often used interchangeably with pharmacogenomics) is also important for drug safety research and identifying potential negative drug-drug or drug-gene interactions.

Biomarkers

Biomarkers are widely used across all forms of clinical practice to indicate that a disease, infection, toxicity, or other process is taking place within an organism.

Biomarkers may include lead levels in the blood, antibodies after an infection, thyroid hormone levels, or prostate specific antigen (PSA), as well as molecular signatures can indicate whether a patient is likely to respond to certain advanced therapies.

The exploration of biomarkers for identifying and treating cancer and similar conditions with genetic components is one of the main branches of precision medicine research.

Biobanking

In many respects, genomic research is at its most useful when conducted at scale. In order to identify patterns in populations in a reliable and repeatable manner, researchers must have access to large volumes of patient data.

In addition, researchers investigating rare genetic conditions or those targeting therapies to very specific populations will only be able to find suitable candidates for clinical trials if they have as many individuals as possible to choose from.

Biobanking, or the act of collecting and storing samples of DNA from groups of individuals (typically blood, saliva, and/or urine), allows researchers to access larger pools of potential subjects who have already signaled a willingness to participate in studies or trials.

Biobanks have proliferated in recent years as healthcare provider systems and government agencies recognize the need to have as much data available for research as possible.

Large health systems such as Geisinger Health System, Northwell Health, and Kaiser Permanente have established their own biobanks to support their research communities, while the Department of Veterans Affairs currently oversees one of the largest biobanks in the country.

The All of Us research initiative, discussed further below, has also launched multiple efforts to kick off its enrollment processes with a special emphasis on collecting data from traditionally underserved communities and ethnically diverse participants.

70% of Orgs Planning Precision Medicine Will Deploy Within 2 Years

Pharma, Tec Companies Set to Restructure Healthcare Big Data Market

2015 was a pivotal year for precision medicine as former President Obama launched the Precision Medicine Initiative (PMI) during that years State of the Union address.

The project, which received bipartisan support at the time, was designed to jumpstart research across the public and private sectors while encouraging everyday patients and their families to get involved in sharing their data and participating in clinical trials.

Iwant the country that eliminated polio and mapped the human genome to lead a new era of medicine one that delivers the right treatment at the right time, Obama said at the time. In some patients with cystic fibrosis, this approach has reversed a disease once thought unstoppable.

Tonight, Im launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes and to give all of us access to the personalized information we need to keep ourselves and our families healthier.

The centerpiece of the initiative was the PMI Cohort, now called the All of Us Research Program. With the goal of recruiting one million Americans to participate, All of Us will eventually provide researchers with access to huge volumes of data to fuel their work.

Researchers will use data from the program to learn more about how individual differences in lifestyle, environment and biological make-up can influence health and disease,said the National Institutes of Health (NIH) in 2017.

By taking part, people will be able to learn more about their own health and contribute to an effort that will advance the health of generations to come.

Socioeconomic, racial, and ethnic diversity are high priorities for the program, which has started to recruit community organizations to spread the word among their participants.

Community partners are integral toAll of Us, said Eric Dishman, Director of the All of Us program. This first-of-its-kind program seeks to include people from all walks of life, and these community partner awardees were selected to help achieve that goal.

The NIH is primarily responsible for overseeing the All of Us project, but is working with conjunction with the FDA, HHS, the Department of Veterans Affairs, Department of Defense, the National Cancer Institute (NCI) within the NIH, and a number of healthcare industry stakeholders to facilitate the Precision Medicine Initiative as a whole.

On a similar theme as the PMI, former Vice President Joe Biden oversaw the launch of the national Cancer Moonshot, supported by funds from the landmark 21st Century Cures Act passed in late 2016.

The Cancer Moonshot aims to use the growing wealth of available healthcare big data to foster breakthroughs in research and cancer treatment. The collaborative effort is bringing together both public and private organizations to support research and develop new treatments for deadly diseases.

Everywhere I travelled [meeting with researchers and patients], I was told that data are key, and we have an unprecedented amount and diversity of data being generated daily through genomics, family history records, lifestyle measurements, and treatment outcomes, said Biden in a 2016 report on the future direction and challenges of the initiative.

We now have the capability to realize the promise of all of these data because of advances in super computing power. Researchers can analyze enormously complex and large amounts of data to find answers we couldnt just five years ago.

CMS may be planning to add even more data to the pool by considering coverage options for a new FDA-approved genetic test that can identify key biomarkers for multiple cancers.

The FoundationONe CDx diagnostic test can flag mutations in 324 genes and two genomic signatures in solid tumors.

The test can also suggest which of 15 existing FDA-approved cancer treatments would be most applicable to patients with one of five tumor types, including non-small cell lung cancer, melanoma, breast cancer, colorectal cancer, and ovarian cancer.

Expanding the availability of such a test to Medicare beneficiaries could rapidly accelerate the goals of both the Cancer Moonshot and the larger Precision Medicine Initiative.

Source: White House Archives

Top 5 Basics to Know about the Precision Medicine Initiative

Mayo Gets $142M to Create Precision Medicine Initiative Biobank

Federal investment is only the beginning of the healthcare systems involvement in furthering precision medicine. The private sector is rapidly embracing similar goals, which align well with existing value-based reimbursement and population health management initiatives.

Academia has been particularly active in the precision medicine ecosystem, combining computer science and engineering breakthroughs with laboratory work and clinical discovery. Similarly, pharmaceutical companies angling to expand their drug portfolios are heavily investing in research and collaborations with healthcare providers and others.

Even Silicon Valley figures like Bill Gates and Mark Zuckerberg are addressing the urgent need for precision medicine development: Gatesrecently announceda $50 million investment in data-driven Alzheimers research, while Zuckerberg and his wife, Dr. Priscilla Chan, madea $10 million donationto the UCSF Institute for Computational Health Sciencesto explore how to best reuse available datasets to produce new insights.

Many activities revolve around collaborations and partnerships between likeminded organizations looking to pool their computing power and share insights across research networks. Some notable examples include:

Geisinger Health Systemhas launchedits own National Precision Health Initiative which will leverage the data from 160,000 volunteer patients held in its MyCode Community Health Initiative biobank. The initiative will focus on developing strategic partnerships and new ventures while harnessing the existing resources within the Geisinger network.

Link:
What Are Precision Medicine and Personalized Medicine?

Read More...

Personalized Medicine Market is Anticipated to Attain a Market Value of US$XX by the End of 2016 2026 – Cole of Duty

Saturday, July 11th, 2020

Global Personalized Medicine market size will reach xx million US$ by 2025, from xx million US$ in 2018, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and 2019-2025 as the forecast period to estimate the market size for Personalized Medicine .

This industry study presents the global Personalized Medicine market size, historical breakdown data (2014-2019) and forecast (2019-2025). The Private Plane production, revenue and market share by manufacturers, key regions and type; The consumption of Personalized Medicine market in volume terms are also provided for major countries (or regions), and for each application and product at the global level.

Request Sample Report @ https://www.futuremarketinsights.co/reports/sample/REP-GB-1511

Global Personalized Medicine market report coverage:

The Personalized Medicine market report covers extensive analysis of the market scope, structure, potential, fluctuations, and financial impacts. The report also enfolds the precise evaluation of market size, share, product & sales volume, revenue, and growth rate. It also includes authentic and trustworthy estimations considering these terms.

The Personalized Medicine market has been reporting substantial growth rates with considerable CAGR for the last couple of decades. According to the report, the market is expected to grow more vigorously during the forecast period and it can also influence the global economic structure with a higher revenue share. The market also holds the potential to impact its peers and parent market as the growth rate of the market is being accelerated by increasing disposable incomes, growing product demand, changing consumption technologies, innovative products, and raw material affluence.

The following manufacturers are covered in this Personalized Medicine market report:

Key Players

Some key players in this market are Roche Holding AG, Astra Zeneca PLC, Vertex Pharmaceuticals Inc., Qiagen Inc., BD (Becton Dickinson & Co., Merck & Co. Inc., Pfizer Inc., American Association for Cancer Research, Siemens Healthcare Diagnostics, Inc. among others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Regional analysis includes

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

APEJ (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Methodology On This Report @ https://www.futuremarketinsights.co/askus/REP-GB-1511

The study objectives are Personalized Medicine Market Report:

We offer tailor-made solutions to fit your requirements, request[emailprotected] https://www.futuremarketinsights.co/customization-available/REP-GB-1511

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Personalized Medicine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Continue reading here:
Personalized Medicine Market is Anticipated to Attain a Market Value of US$XX by the End of 2016 2026 - Cole of Duty

Read More...

Real-world data coming into its own despite bad reputation in times gone by – BioWorld Online

Saturday, July 11th, 2020

The use of real-world data (RWD) and real-world evidence (RWE) in regulatory decision-making may seem more aspirational than practical at times, but that state of affairs is changing rapidly. Wendy Rubenstein, director of personalized medicine at the U.S. FDAs Center for Devices and Radiological Health, said contemporary versions of these real-world sources of evidence are of progressively higher quality in recent years, and thus RWE and RWD may soon hit their strides as mature sources of data with which regulators are increasingly comfortable.

Rubenstein was speaking on a recent webinar hosted by the Medical Device Innovation Consortium, the public-private partnership between the FDA and device makers with the objective of modernizing regulatory science. The theme of the webinar was a framework developed by MDIC for the use of RWE and RWD for in vitro diagnostics, and Rubenstein said that for perhaps the majority of randomized, controlled trials, the benefit is generally diluted when that therapy or diagnostic is rolled out for routine clinical use. The external validity of the results of studies is not always sufficiently vigorous to withstand translation into general clinical use, particularly when the enrolled study population fails to reflect the population(s) that will use or receive the device, she said.

Collection of RWD in the premarket phase should help mitigate these problems and more accurately predict similar results in real-world settings, Rubenstein said, adding that RWDs reputation has not always been the best and has maybe got a bit of a bad rap as a consequence. Recently, however, the increasing quality of RWE and RWD is changing minds, and Rubenstein said the process involved in developing the MDIC framework is helping us get to that higher level.

Pandemic has quickened stakeholder interest

The FDA has given the nod to more than 100 diagnostic emergency use authorizations (EUAs) in connection with the COVID-19 pandemic, and Rubenstein said the pandemic has had the effect of unifying the purpose of regulators and test developers alike. COVID-19 can actually result in driving the community toward a common purpose of generating evidence on real test performance for molecular diagnostics for the SARS-CoV-2 virus, she said, but this will require a definition of common data elements to support use purposes. Still, Rubenstein advised that the pandemic is likely to come to an end before stakeholders can stand up a fully developed infrastructure needed to make routine use of RWD.

In other words, theres an opportunity to use the activation energy created by the pandemic to build an infrastructure that will extend beyond COVID, Rubenstein said. However, all of this will require the use of the Standardization of Lab Data to Enhance Patient-Centered Outcomes and Value-Based Care (Shield) project. Shield is another public-private partnership, and is focused on data lab standards, and is one of the pillars needed to make the data accessible. The development of mapping manuals for logical observation identifier names and codes (LOINCs) will also prove crucial because of a considerable amount of ambiguity with regard to LOINCs, which has up to now has made it difficult to aggregate data about a tests routine clinical use, sometimes even within a health care organization.

Danelle Miller, director of global regulatory policy at Indianapolis-based Roche Diagnostics Corp., and chair of the RWE working group (WG) at MDIC, made reference to the August 2017 FDA guidance for the use of RWE to support regulatory decision-making. Miller said industry welcomed the FDA guidance enthusiastically, largely because the guidance goes a long way toward clarifying when RWE can be leveraged for regulatory decision-making. She said the MDIC framework represents years of hard work and robust discussions among the parties, including industry, the FDA and the Centers for Disease Control and Prevention. The comment period for the MDIC framework closes June 15.

The scope of the framework is largely limited to the current landscape for RWE and real-world data (RWD) and, in the case of the latter, how it can be used for both premarket regulatory decision-making and for postmarket issues. The framework also proposes and approach for evaluating the relevance and reliability of RWD to assess data quality for regulatory decisions, and proposes a few study designs and methods for generating valid scientific evidence.

The task for the work groups included development of a glossary for RWE and RWD, as well as a survey to determine how IVD manufacturers are currently using RWE throughout product life cycles. The WG undertook a literature search for use of RWE and RWD, but there was a considerable amount of effort put into a description of the requirements for data quality and the methods for using RWD.

Alternative study designs available

One of the complicating factors in leveraging real-world sources of evidence for diagnostics in the premarket phase is that diagnostic studies dont often strongly resemble the types of trials employed for therapeutic devices. One approach to overcoming this limitation is the use of a virtual clinical performance study, which can be used to support premarket approval or clearance of an IVD. The MDIC paper spells out several other approaches as well, but among the regulatory considerations for any of these studies is whether the data are fit for the purpose at hand.

The assessment to determine whether those data are fit for purpose includes a determination of whether the data are both accurate and complete, and whether those data meet key reliability and relevance criteria to support the sought-after regulatory decision. Test developers should also ensure they are using data standards the FDA will accept, and may want to engage with the agency via the Q-submission process to clear out any potential issues before the developer invests more than a modest amount of resources toward the application.

Visit link:
Real-world data coming into its own despite bad reputation in times gone by - BioWorld Online

Read More...

Drug Discovery Informatics Market Size Estimation, Future Insights, Growth Dynamics, COVID-19 Impact and Applications By 2023 – Cole of Duty

Saturday, July 11th, 2020

Drug Discovery Informatics MarketScope

The GlobalDrug Discovery Informatics Marketstood at USD 1,680.6 million in 2017. It is expected to enjoy a high valuation at a 11.5% CAGR from 2018 to 2023 (forecast period). Factors driving market growth include impending need to curtail drug discovery and development costs, focus on drug discovery, increasing expenditure on R&D, and large prevalence of chronic diseases. According to the WHO report of 2001, chronic diseases accounted for 60% of the deaths that year. Nearly 46.4% of the deaths in 2020 will be credited to chronic diseases triggering the market demand. But setup of laboratories and high costs of informatics software can restrict the market growth.

Drug discovery plays a vital role in the life sciences, pharmaceutical, and biopharmaceutical industries. The amount of data accumulated from clinical trials and tests is vast and requires software to sift through. New approaches in drug discovery informatics for accumulating and processing information can lead to faster commoditization of drugs, medicines, and vaccines. The global drug discovery informatics market report by Market Research Future (MRFR) contains a comprehensive overview followed by pertinent factors and drawbacks for the period between 2018 and 2023.

Request Free Sample Copy at:https://www.marketresearchfuture.com/sample_request/7831

Drug Discovery Informatics MarketSegmentation

The global drug discovery informatics market is segmented by product, mode, service, and end-user.

By product, drug discovery informatics market is segmented into discovery informatics and development informatics.

By mode, drug discovery informatics market is is divided into in-house informatics and outsourced informatics.

By service, drug discovery informatics market is is segmented into clinical trial data management, sequencing and target data analysis, molecular modeling, docking, and others. The sequencing and target data analysis segment is touted to dominate the market during the forecast period due to increasing applications in targeted analysis. Inclination towards personalized medicine is bound to drive the segment demand and contribute to the global drug discovery informatics market growth.

By end-user, drug discovery informatics market is is segmented into contract research organizations, pharmaceutical & biotechnology industries, and others.

Drug Discovery Informatics Market Regional Analysis

Europe, Asia Pacific (APAC), the Americas, and the Middle East & Africa (MEA) are regions covered in the global drug discovery informatics market report.

The Americas dominated the global market in 2017 due to presence of prominent names such as International Business Machines, PerkinElmer Inc., and ThermoFisher Scientific Inc. Establishment of next-generation sequencing and chemical laboratories in the U.S. and Canada, boom in pharmaceutical and biopharmaceutical industries, and sophisticated healthcare infrastructure.

Europe is the second largest region and highly lucrative for the global drug discovery informatics market till 2023. This can be credited to funding allocated to research and development on drug research by governments, growth in therapeutic discovery centers, and successful activities by research and academic institutes, universities, and other prestigious centers.

APAC can be ensured to display a profitable growth rate during the forecast period due to the large geriatric population and heavy prevalence of chronic diseases. Awareness of the software, adoption of the software in pharma and biopharma companies, and a rise in clinical studies can drive the regional market growth. Lower costs, lax policies and regulations, and a spurt in clinical trials are other factors making the region lucrative for the global drug discovery informatics market.

Drug Discovery Informatics Market Competitive Outlook

Certara, L.P., Charles River Laboratories, Inc., Jubilant Life Sciences Ltd., Novo Informatics Pvt. Ltd., Dassault Systmes, IO Informatics, Inc., Thermo Fisher Scientific, Inc., Infosys Limited, Selvita, International Business Machines Corporation, PerkinElmer, Inc., Collaborative Drug Discovery Inc., and GVK Biosciences Private Limited are prominent players of the global drug discovery informatics market.

Drug Discovery Informatics Industry News

Schrdinger, a U.S. based drug discovery company, recently received nearly USD 232 million in funding in January 2020. The platform developed by the company can assess the chemical composition of molecules and predict the properties during mixing and expedite the process rapidly saving production costs in the process.

Browse More Details at:https://www.marketresearchfuture.com/reports/drug-discovery-informatics-market-7831

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [emailprotected]

Read the rest here:
Drug Discovery Informatics Market Size Estimation, Future Insights, Growth Dynamics, COVID-19 Impact and Applications By 2023 - Cole of Duty

Read More...

What’s working in the APAC countries’ fight against cancer? – World Economic Forum

Saturday, July 11th, 2020

The battle against COVID-19 is dominating our attention right now and rightly so. The pandemic is impacting economies, societies and individuals across all sectors, but especially in healthcare. However, while we focus on tackling the pandemic, it is critical that we dont lose sight of our efforts to address the devastating impact of other diseases, such as cancer.

With healthcare systems focused on the fight against COVID-19, we are witnessing disruption across the spectrum of cancer care and delivery. There are multiple contributing factors, ranging from closures of screening programmes to public transport lockdowns hindering access to health facilities, delays to important consultations leading to disease progression and high rates of sickness among health workers dramatically reducing the numbers of available staff. Cancer patients are also more vulnerable to becoming severely ill or dying from COVID-19 and many, understandably, fear coming into hospitals or clinics during this time.

Nowhere is the battle against cancer fought more bitterly than in Asia Pacific (APAC). Almost half of the worlds cancer cases are found here, and by 2030 the number of people battling cancer is expected to surge by around 35%, with mortality rising by almost 40%. COVID-19 has emphasised the importance of making health systems robust and sustainable in the long-term, so that the impact of care delivery for non-communicable diseases like cancer is minimized during this and future outbreaks.

When addressing significant public health issues like COVID-19, cardiovascular disease or cancer can sometimes feel like an insurmountable challenge for countries faced with limited resources and competing priorities.

A new report from the Economist Intelligence Unit (EIU), supported by Roche, analyses the readiness of 10 APAC countries to address the cancer challenge. The report highlights existing gaps and progress made with recommendations on how to boost this progress towards more sustainable and equitable cancer care. Advances in cancer planning and preparedness vary across countries, but the improvements highlighted span several areas from research and policy development to the expansion of national cancer registries and implementation of universal health coverage (UHC) programmes.

Australia ranks highest of all countries evaluated for overall cancer preparedness, followed by Malaysia, South Korea, China and Thailand. This success is due in part to these countries demonstrating strong examples of cancer registries, which play a vital role in generating meaningful, evidence-based, long-term planning for cancer. The Philippines stands out as one of the only lower-middle-income countries evaluated with a comprehensive cancer plan.

Cancer preparedness in APAC

Image: Economist Intelligence Unit, Roche

We also see a strong link between a countrys cancer readiness and its overall healthcare spending. Indonesia and Malaysia showed strong commitment in this area; they registered the strongest growth in healthcare spending of all the countries evaluated, with average annual increases of 5.7% and 3.2% respectively. The WHO notes higher government spending on health is also associated with lowering income inequality, in particular for fast-growing countries.

Spending more on health is a way to reduce inequality

Image: WHO Health Expenditure Report 2019

UHC generates benefits to societies far beyond the health sector, strengthens health systems governance and improves overall population health outcomes. Across Asia, positive steps have been taken towards universal access to cancer care. Thailand demonstrates strong implementation of UHC programmes alongside higher-income countries like Australia, South Korea and Japan. Thailand is also the only country evaluated in which all cancer medicines were found to be fully accessible and reimbursable via their public health system, an impressive achievement unmatched even in highly developed nations. This increased focus on UHC programmes is in line with the recent WHO report that recommends the inclusion of prevention, early diagnosis, screening and appropriate treatment of non-communicable diseases in essential personalised healthcare services and UHC benefit packages.

Theres no getting away from the fact that the COVID-19 crisis has magnified healthcare challenges for populations and, in turn, policy and decision-makers. So how do we double down on this progress in a post-COVID-19 world to ensure we continue along a faster, upwards trajectory?

Gaps in service availability experienced by middle-income countries like China, Malaysia, Indonesia and the Philippines, including the under-provision of equipment, oncology specialists and infrastructure, are a major area of opportunity. If COVID-19 has shown us anything, it is that digital technology can play a critical role in addressing these gaps. The pandemic has forced healthcare systems to adopt new ways of working, to ensure cancer patients continue to receive essential care. Places like Thailand and Hong Kong are reaching more patients in need through the launch of virtual clinics and teleconsultations for remote areas. Australia and China are harnessing artificial intelligence to aid faster, more accurate diagnosis.

There is also a clear need to establish strong, cross-sector partnerships to collaborate on research and invest in areas like big data analytics and personalised medicine to significantly improve patient outcomes.

In Taiwan, for instance, Roche is partnering with the government to foster personalized healthcare with a focus on tailoring cancer treatment to individual patients for the best outcomes. The objective is to provide targeted treatment through precise genomic analysis and to reduce unnecessary medical expenses while improving the quality of healthcare.

Each year, $3.2 trillion is spent on global healthcare making little or no impact on good health outcomes.

To address this issue, the World Economic Forum created the Global Coalition for Value in Healthcare to accelerate value-based health systems transformation.

This council partners with governments, leading companies, academia, and experts from around the world to co-design and pilot innovative new approaches to person-centered healthcare.

While progress is undoubtedly being made in tackling the cancer challenge across APAC, there is still a long way to go. Excess cancer mortality remains a serious concern for lower-and middle-income countries. Cancer not only takes lives but also can result in severe economic hardship.

As someone who has spent a significant amount of time in healthcare and seen first-hand the devastating impact of the pandemic on cancer patients, I believe that a data-driven future holds the most potential to build resilient health systems for the future. Better data can help us work smarter and faster to respond to issues like COVID-19 and future health challenges. Digital and personalised healthcare can play an important role in advancing UHC, making health systems more sustainable, efficient and accessible and allowing policy-makers to better optimise resources.

Reducing the cancer burden requires an integrated, cross-sector, global response. This means creating systemic change in our healthcare ecosystems, and reorienting our relationships with the government, the outside world, and even with each other. While testing the limits of our health systems, COVID-19 has also highlighted the incredible achievements possible when we all band together.

See more here:
What's working in the APAC countries' fight against cancer? - World Economic Forum

Read More...

Demand for Anti Cd2-0 Monoclonal Antibodies Market to Witness Rapid Surge During the Period 2017 2025 – Cole of Duty

Saturday, July 11th, 2020

Anti-CD20 monoclonal antibodies are widely used in the treatment of B-cell malignancies. Anti-CD20 monoclonal antibodies are advantageous as they have enhanced killing activities and improves CD20 levels on the cell surface to increase the activity of lymphoma therapy. Since the inception of monoclonal antibodies, various type of potential mechanisms has been developed to increase the therapeutic efficiency of anti-CD20 monoclonal antibodies. This laid emphasis on developing next generation of anti-CD20 monoclonal antibodies to supplement additional potency in terms of functionality and efficacy. Anti-CD20 monoclonal antibodies work by targeting expressed CD20 marker on mature B cells and malignant B cells. This cascade of series works by complementing with the marker to deliver immunological attack from complement and FcR-expressing innate effectors (macrophages). This result in producing transmembrane signals by CD20 on engagement with anti-CD20 monoclonal antibodies, this favorable mechanism is utilized in malignant disease and autoimmune disorder treatment. Potential benefits from anti-CD20 monoclonal antibodies laid emphasis on developing next-generation anti-CD20 monoclonal antibodies and are currently in clinical trials.

To remain ahead of your competitors, request for a sample [emailprotected]https://www.persistencemarketresearch.com/samples/20833

The market for anti-CD20 monoclonal antibodies is primarily driven by increasing research and development activities in generating potent anti-CD20 monoclonal antibodies. Various research funding and grants, and investment are done by both private and government bodies to support R&D activities and are driving the growth of anti-CD20 monoclonal antibodies market. In addition, rising demand for personalized medicine coupled with increasing use of immunotherapy, and potential benefits from the treatment in terms of fewer side effects, low cost of production are also impelling the market growth of anti-CD20 monoclonal antibodies. However, the high cost of production, the presence of alternative therapies such as chemotherapy and drugs, and stringent rules and regulations are the major obstacles to the growth of anti-CD20 monoclonal antibodies market.

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/20833

The global anti-CD20 monoclonal antibodies market can be segmented on the basis of product type, end-user, and region.

The introduction of monoclonal antibodies has revolutionized targeted therapy for cancer. Since its introduction, various technological advancement has been made in generating a novel products such as next generation anti-CD20 monoclonal antibodies are humanized monoclonal antibodies, whereas first generation anti-CD20 monoclonal antibodies are chimeric monoclonal antibodies. In addition, some of the anti-CD20 monoclonal antibodies are enhanced to improve effector functions, including improvement in FcR binding sites. The emergence of logistic services and e-commerce websites are also a vital component in boosting the growth of anti-CD20 monoclonal antibodies market.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/methodology/20833

Geographically, global anti-CD20 monoclonal antibodies market can be segmented into North America, Latin America, Europe, Asia-Pacific and Middle East & Africa. The market in North America is anticipated to show the largest market share for anti-CD20 monoclonal antibodies, followed by Europe, owing to the presence of sophisticated healthcare infrastructure. In addition, proper reimbursement of therapy procedure, and increasing awareness about personalized medicine among the general population are also gardening the market growth of anti-CD20 monoclonal antibodies. The market in Asia-Pacific region is estimated to grow at fastest CAGR over the forecast period owing to the presence of large population base, and increasing research and development activities supported by private and public bodies. However, the market in the Middle East & Africa shows the steady growth during the forecast period.

Some of the market participants in the global anti-CD20 monoclonal antibodies market are

Read the original here:
Demand for Anti Cd2-0 Monoclonal Antibodies Market to Witness Rapid Surge During the Period 2017 2025 - Cole of Duty

Read More...

[Webinar] The Dos and Donts of Power of Attorneys and Living Wills – July 22nd, 12:00 pm – 1:00 pm ET – JD Supra

Friday, July 10th, 2020

July 22nd, 2020

12:00 PM - 1:00 PM ET

Whether you have been named power of attorney or have named someone to act as yours, it is crucial to understand the legal obligations and restrictions of power of attorney and living wills.

In this webinar, Whitney OReilly will provide tips and tricks for getting the most out of your power of attorney or living will, from making sure the appropriate parties are informed of their role to establishing a way of communicating the directives to hospitals, living facilities, and financial managers. She will highlight some of the key questions individuals should ask in the process of determining their power of attorney and creating living wills and will review the impact recent legislation has had on the power of attorney and living wills.

This webinar will feature a brief Q&A with Michael Snyder, who recently worked with the firm to manage the legal ramifications of sickness and death. Michael is the chair of the Department of Genetics and the director of the Center for Genomics and Personalized Medicine at Stanford University School of Medicine.

Read more:
[Webinar] The Dos and Donts of Power of Attorneys and Living Wills - July 22nd, 12:00 pm - 1:00 pm ET - JD Supra

Read More...

NantHealth Points To The Future Of Healthcare – Seeking Alpha

Friday, July 10th, 2020

MantHealth (NH) offers cancer molecular profiling solutions that enable personalization in a number of cancer treatments. This business, which has been lingering for a couple of years has received an important FDA approval which makes approval for Medicare and Medicaid use very likely. This, together with the sale of their Connected Care business has boosted the stock price significantly, but we think it's not too late to step on board.

The company is also is enabling a more integrated and data-driven healthcare solution through its two SaaS platforms, which are growing and account for most of the company's revenues to date.

These proven integration solutions are offered to an industry, which as they claim (and, dare we say, not without reason) suffers from a host of unnecessary complexity and inefficiencies, most notably:

Because of these inhibitions, the healthcare system is struggling to make the shift towards a more holistic, data-driven approach, the culmination of which is individualized medicine.

Personalized medicine is based on personalized data that is increasingly becoming available through advances in molecular medicine and real-time biometrics (remote monitoring devices and the like).

These solutions, like the company's own GPS business, generate a veritable deluge of data which, for a coordinated and individualized approach need to be collected, analyzed and distributed, and it's here where the company's SaaS solutions intervene and add value. We'll quickly introduce the company's solutions below.

From the 10-K:

GPS Cancer is a comprehensive molecular profile that integrates whole genome/exome (DNA) sequencing of tumor and normal germline samples and whole transcriptome (RNA) sequencing, providing oncologists with insights into the unique molecular signature of a patients cancer to inform personalized treatment strategies.

What GPS Cancer does is comparing the patient's whole genome/exome sequencing of a persons tumor sample with their normal sample in order to highlight molecular alterations that are specific to their tumor DNA.

These alterations are then subsequently confirmed by RNA sequencing. All this enables the matching of these alterations with drugs that might be effective against tumors containing the specific change. And these solutions are constantly fine-tuned by machine learning.

This is the company's blood based test that allows non-invasive profiling of tumors and monitoring quantitative response to treatment, from the 10-K:

Liquid GPS looks beyond cfDNA to cfRNA, which allows profiling and trending of actionable biomarkers that cannot be assessed through cfDNA alone. In addition to providing molecular insight into key guidelines-based biomarkers (e.g., EGFR, ALK, ROS1, KRAS), this powerful RNA-based approach enables a variety of capabilities and applications not typically available from a liquid biopsy test.

It is able to monitor targeted therapies, immunotherapy and chemotherapy responses.

This is the company's SaaS based decision support system which provides evidence-based clinical decision support for physicians who are threatened to be overwhelmed by today's rapid advancements in molecular and biometric medicine.

Eviti centralizes stuff like clinical content, treatment cost from Medicare reimbursements and treatment toxicity data. It has access to over 7600 clinical trials and 4000+ evidence-based treatment regimes.

NaviNet Open is a payer-provider workflow collaboration platform in order to increase efficiency, lower cost, improve provider satisfaction and enable communication between health plans and providers.

The company sold its Connected Care business for $47M in February to Masimo (MASI), exiting DCX, VCX, HBox and Shuttle Cable. The Connected Care business generated $1.2M in sales in Q1, a small part of overall revenue ($23M).

While operational performance has improved, the company hasn't been able to grow much in the past four years:

Data by YCharts

After the sale of its Connected Care business, the company has two revenue categories:

To date, the company's SaaS revenue generates most of its revenue but it does gain some revenue from sequencing and molecular analysis. However, last quarter saw a big decline to just $59K (down from $814K a year ago).

The stagnant revenue in part is just appearance as the company's SaaS business has been growing, from $60.7M in 2017 to $65.6M in 2018 to $72.8M in 2019, because the company de-emphasized its GPS business as costs were outweighing revenues. The company keeps on adding new customers (like here and here) to its SaaS businesses, a few were mentioned on the Q1CC.

The company keeps improving their products and adding new Eviti and NaviNet features.

For this business to take off, the wait is basically for a positive coverage determination from CMS, from the Q1CC:

we expect to continue to see minimal sequencing and molecular analysis revenue impact until we receive a positive coverage determination from CMS.

However, that event seems near, from the 10-K (our emphasis):

In the fourth quarter of 2019, we received FDA 510(K) authorization for Omics Core, the nations first FDA authorized whole exome tumor-normal in vitro diagnostic (IVD) that measures overall tumor mutational burden (TMB) in cancer tissue, completing a key step towards achieving Medicare coverage.

Which, together with the sale of the Connected Care business, explains the rally in the shares, from FinViz:

It's GPS business generated $2.55M in revenues in 2017, $3.13M in 2018 and $1.73M in 2019. Here too, apart from the FDA approval for Omics Core, there are other developments and improvements.

The company launched a new AI platform which can automatically distinguish sub-types lung cancer pathology and improves on that ability, from PR:

Derived from deep-learning models, together, the findings demonstrate a novel AI-based method for subtyping lung cancer pathologies which impacts treatment options for patients and improved methods of identifying tumor infiltrating white cells found elevated in lung cancer.

Accurately identifying and quantifying tumor-infiltrating white cells is extremely important for prognosis and treatment decisions in this era of personalized medicine, yet it currently requires manual review of whole slide images by medically trained pathologists, and incurs significant delays and cost, explains Dr. Patrick Soon-Shiong, MD, Chairman and CEO of NantHealth.

And they are working on a similar solution for breast cancer. In principle, their TMB (tumor mutational burden) test capability is a generic capability with wide application scope, here is a description of the mechanics from company PR:

Omics Core reports a cancer patient's overall TMB by sequencing and comparing 19,396 protein-coding genes targeting 39 million base pairs of the human genome from a tumor sample and a normal sample, typically from blood or mucosal membrane. TMB indicates the sum of all acquired gene-coding mutations in a tumor genome and is increasingly used to predict response to therapy and identify tumors that could benefit from immunotherapy. In addition, the test reports somatic mutations in 468 cancer-relevant genes accurate to 2% allele frequency, to inform clinical decisions about patient treatment. "Tumor mutation burden ... is now recognized as a key biomarker across multiple tumor types," said Patrick Soon-Shiong, chairman and CEO of Nanthealth. "Studies have shown that immunotherapy treated with high TMB had better outcomes compared to those with low TMB."

And here is a description of a peer reviewed article how this improves targeting capabilities of treatments. It's the more general applicability of TMB and the FDA approval that shareholders are rejoicing.

According to management, two things stand out (PR, our emphasis):

Nanthealth is positioning its tumor-normal test as an advancement over competitors like Myriad Genetics Inc., Color Genomics Inc. and Invitae Corp., which have limited gene panels to look at hereditary risk. By sequencing the whole exome, "we have the ability to identify things that others are missing, and that's particularly critical for drug development," Sandeep Reddy, Nanthealth's chief medical officer, told BioWorld MedTech. "We know about maybe cancer risk, but what do we know about autism or Alzheimer's? By getting that information, that becomes transformative."

As described in that PR, the company's TMB test spots things that other solutions don't, resulting in a more personalized approach to what therapies might be more successful, and it has applicability beyond screening for cancers.

But from a financial point of view, things are also going pretty well.

Data by YCharts

GAAP margins have been trending up and gross margin was much better than a year ago (60% versus 49%), up on product mix (the shift towards its SaaS business).

Operating expenses declined from $20.2M in Q1 2019 to $16.8M in Q1 2020, but $1.1M of that decline is related to the sold Connected Care business.

While cash flow is still negative, there has been tremendous improvement in the last 2.5 years.

Data by YCharts

The net cash burn in Q1 was still around $5M, but this included various closing costs and other front-end loaded costs in relation to the sale of the Connected Care business.

And with that sale the balance sheet has improved a lot, with the company having $47.5M in cash on the books, although the company does have a substantial $95.3M in long-term debt, from the 10-Q:

Data by YCharts

The valuation has jumped along with the share price recently but we think it's still not excessive, it has been much higher in the past on a much more distant promise of monetizing their TMB solutions and in the meantime the company developed a successful SaaS business with their Eviti and NaviNet platforms.

With a backwards looking EV/S of 8X for a company with a unique product that is about to get monetized and a successful SaaS business is high, but not overly so. Analyst still expect EPS losses, $0.23 this year falling to -$0.18 next year, but the company doesn't burn much cash and has plenty of it.

While much is uncertain about the potential of the company's GPS business and the economics of it, the company does have unique capabilities that are likely to become important tools in fighting a number of cancers and the underlying capabilities seem to have wide applicability.

Add to that an attractive SaaS business a declining cash burn and the sale of its Connected Care business providing enough cash to keep the company going for the foreseeable future, and we think we still have an attractive proposition for shareholders, even if it looks like the shares might want to have to digest recent strong gains.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Excerpt from:
NantHealth Points To The Future Of Healthcare - Seeking Alpha

Read More...

IM Therapeutics Expands Management Team with Appointments of Tom Shea as CFO/COO and Dr. Sarah Bird as VP, Clinical Development – Business Wire

Friday, July 10th, 2020

WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (IM Therapeutics), a leading innovator in the field of precision medicine for autoimmune disease, announced today that Mr. Tom Shea and Dr. Sarah Bird have joined its senior management team. Tom has joined as Chief Financial Officer and Chief Operating Officer (CFO/COO) and Sarah has been promoted to the position of Vice President, Clinical Development.

Tom has over 30 years of professional financial experience ranging from early-stage start-ups to commercial-stage and publicly traded companies. Most recently, Tom served as CFO of ImmusanT, a clinical stage therapeutic company in celiac disease and type 1 diabetes. He has served as CFO and has been involved in growth operations of a number of biotech companies, most notably Albireo Pharma, developing products for children with severe liver diseases, Tolerx, Inc., an immunology company focused on type 1 diabetes, and Cubist Pharmaceuticals, an infectious disease company. Over his career, Tom has led executive teams in raising significant capital and completing transactions for strategic collaborations. In addition, Tom has served as a Board Member of the New England chapter of JDRF, a world-renowned foundation devoted to the treatment and cure of T1D.

Sarah joined IM Therapeutics at its founding stage to help design and lead its clinical program development as Director, Clinical Development. She is a seasoned professional with over 20 years experience leading programs in basic, translational and clinical research. She has worked in academia, biotech and device industries in technologies from start-up to commercial stage. In her graduate and postdoctoral work at St Louis School of Medicine and later as a JDRF Fellow at the U. of Colorado, her research focused on autoimmune pathogenesis and potential therapeutic approaches. Sarah has led global programs at Medtronic, Gilead and pharmaceutical companies in both clinical and medical affairs managing cross-functional teams responsible for strategy, planning and execution. Sarah has led teams overseeing regulatory submissions and product approvals while actively raising physician and patient awareness in areas of unmet medical need.

I am excited to be working closely with Sarah and Tom as we advance our clinical programs and grow our pipeline, said Nandan Padukone, Ph.D., CEO of IM Therapeutics. Both Tom and Sarah have shown a great commitment to T1D and to bringing new drug programs in autoimmune disease to the clinic.

I find the underlying biology that genetically targets specific autoimmune pathogeneses to be fascinating and a unique opportunity to translate to clinical practice, said Dr. Bird. It is great to work with highly motivated people to impact patient care and personalized medicine, she added.

Mr. Shea further added, Ive had a long-standing interest in helping to progress companies working within the autoimmune space. I am pleased to be a part of this team and very hopeful of the targeted approach we are testing in T1D and other autoimmune diseases.

The Company recently announced that the first subject was dosed in a Phase 1 study of its lead drug, IMT-002, an oral drug designed as a selective HLA-DQ8 blocker for treatment of T1D and DQ8-related disease.

About IM Therapeutics

IM Therapeutics is a clinical stage company developing personalized medicines for autoimmune diseases by building oral drug therapies against human leukocyte antigen (HLA) variants that confer high risk of disease. The Company platform screens millions of compounds for optimal docking within HLA proteins together with rational drug design and bioassays to develop targeted therapeutic candidates. In addition to its lead drug, IMT-002, directed at HLA-DQ8 activity for treatment of type 1 diabetes, the Company is building a broad pipeline of drugs against HLA targets such as DQ2, DR3 and DR4 in a range of autoimmune disorders including celiac disease. http://imtherapeutics.com/

Go here to read the rest:
IM Therapeutics Expands Management Team with Appointments of Tom Shea as CFO/COO and Dr. Sarah Bird as VP, Clinical Development - Business Wire

Read More...

CSL Behring Announces Professor Heimburger Awards in Advance of ISTH 2020 Virtual Congress – PRNewswire

Friday, July 10th, 2020

KING OF PRUSSIA, Pa., July 9, 2020 /PRNewswire/ --Global biotherapeutics leader CSL Behring today announced the recipients of its 2020 Professor Heimburger Awardfor coagulation research just ahead of the first ever virtual congress of the International Society on Thrombosis and Hemostasis (ISTH).

The annual global Professor Heimburger Awards program recognizes the clinical and/or preclinical research of emerging coagulation specialists who are driven to improve the care of patients with bleeding disorders.The program demonstrates the company's continuing promise to support pioneering research by providing a 20,000 (~$22,500) research grant annually, to each of five recipients. This year's recipients are:

"Our leadership in hemophilia and other bleeding disorders starts with innovative science and extends beyond what is happening in our own labs or product portfolio to advance research and patient care across the globe," said Antti Kourula, Vice President, Hematology Therapeutic Area, CSL Behring."We look forward to the exciting research the Heimburger Awards supports."

In addition, CSL Behring will highlight its continued commitment to scientific research and innovation by participating as a Gold level sponsor at ISTH 2020 Virtual Congress. During the Congress, CSL Behring will host two symposia and two product theaters, along with supporting eight posters. (Full abstracts may be reviewed at https://abstracts.isth.org/)

CSL Behring Supported Symposia & Product Theaters (Tuesday, July 14, 2020)

CSL Behring Supported Posters

About the CSL Behring Professor Heimburger AwardsProfessor Norbert Heimburger was an employee of CSL Behring for more than 30 years and devoted his work to blood coagulation. One of his major contributions in this area was the development of virus-safe plasma products based on pasteurization, a development that led CSL Behring to produce the world's first virus-inactivated factor VIII concentrate to treat patients with hemophilia. More information about the Professor Heimburger Awards, including application information for 2021 can be found at: https://www.cslbehring.com/r-and-d/awards-and-grants/professor-heimburger-award

About CSL BehringCSL Behringis a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 26,000 people, anddelivers its life-saving therapies to people in more than 100 countries. For inspiring stories about the promise of biotechnology, visit Vita CSLBehring.com/vita and follow us on Twitter.com/CSLBehring.

SOURCE CSL Behring

Link:
CSL Behring Announces Professor Heimburger Awards in Advance of ISTH 2020 Virtual Congress - PRNewswire

Read More...

How Patient Engagement Technology is Transforming the Healthcare… – Healthcare Tech Outlook

Friday, July 10th, 2020

The healthcare sector has started to utilize the patient engagement technology so that they can offer them with better treatments.

FREMONT, CA:Technology is continuously changing the face of the healthcare industry at an extremely high rate. If the new technologies are utilized effectively, healthcare organizations will meet the increasing demand and efficiently offer better service to the patients. Here are some of the trends related to patient engagement technology that the healthcare sector can follow.

Utilization of artificial intelligence (AI) and machine learning

Presently, the healthcare sector has also started to utilize technologies like machine learning and AI. However, it is expected that the utilization of these technologies will increase rapidly in the coming years and offer various benefits. Moreover, if the sector enhances their research and clinical trials' efficiency by developing new tools, it will help them to fulfill the demands of the patients and even make the process cost-efficient.

The opinion about technologies like chatbots is also changing because the patients can directly book their appointments or solve their queries related to medications. Moreover, Conversational AI will also help the patients and the healthcare providers to converse among each other through written or spoken language.

Advancement of personalized treatment using predictive medicine

Presently various new applications are coming up that are prioritizing predictive healthcare so that the patients get introduced to more effective treatments. Wearables are a useful technology that can be used for capturing the data for treatment purposes. Therefore, the healthcare sector is applying wearable technologies to create opportunities for organizations to offer personalized treatment to the patients.

Furthermore, the data that has been collected from the smartwatches and trackers will allow the healthcare facilities to get a better idea and start treatment of the issues in advance before it starts showing symptoms in the patients. The doctors can also prescribe the medications accurately due to precision medicine as it is data driven.

The continuous growth of digital platforms

As the consumers want a better and sophisticated service so that they can manage their necessities, the popularity of the all-in-one platform is increasing. In the healthcare sector, the consumers are also expecting a user-friendly and customer-first digital experience, and this all-in-one platform can offer them with it.

However, in the healthcare sector, it is necessary to apply the new technologies in their present business model and IT infrastructure to offer better treatment to their patients.

See also:Top Machine Learning Companies

See original here:
How Patient Engagement Technology is Transforming the Healthcare... - Healthcare Tech Outlook

Read More...

Why are scientists trying to manufacture organs in space? – The Conversation US

Friday, July 10th, 2020

Gravity can be a real downer when you are trying to grow organs.

Thats why experiments in space are so valuable. They have revealed a new perspective into biological sciences, including insights into making human tissues.

Gravity influences cellular behavior by impacting how protein and genes interact inside the cells, creating tissue that is polarized, a fundamental step for natural organ development. Unfortunately, gravity is against us when we try to reproduce complex three dimensional tissues in the lab for medical transplantation. This is difficult because of the intrinsic limitations of bio-reactors used on Earth.

I am a stem cell biologist and interested on brain health and evolution. My lab studies how the human brain is formed inside the womb and how alterations in this process might have lifelong consequences to human behavior, such as in autism or schizophrenia. Part of that work includes growing brain cells in space.

To build organized tissues in the lab, scientists use scaffolds to provide a surface for cells to attach based on a predetermined rigid shape. For example, an artificial kidney needs a structure, or scaffold, of a certain shape for kidney cells to grow on. Indeed, this strategy helps the tissue to organize in the early stages but creates problems in the long run, such as eventual immune reactions to these synthetic scaffolds or inaccurate structures.

[Deep knowledge, daily. Sign up for The Conversations newsletter.]

By contrast, in weightless conditions, cells can freely self-organize into their correct three-dimensional structure without the need for a scaffold substrate. By removing gravity from the equation, we researchers might learn new ways of building human tissues, such as cartilage and blood vessels that are scaffold-free, mimicking their natural cellular arrangement in an artificial setting. While this is not exactly what happens in the womb (after all the womb is also subject to gravity), weightless conditions does give us an advantage.

And this is precisely what is happening at the International Space Station.

These experiments help researchers optimize tissue growth for use in basic science, personalized medicine and organ transplantation.

But there are other reasons why we should manufacture organs in space. Long-term space missions create a series of physiological alterations in the body of astronauts. While some of these alterations are reversible with time, others are not, compromising future human spaceflights.

Studying astronauts bodies before and after their mission can reveal what goes wrong on their organs, but provides little insights on the mechanisms responsible for the observed alterations. Thus, growing human tissues in space can complement this type of investigation and reveal ways to counteract it.

Finally, all forms of life that we know about have evolved in the presence of microgravity. Without gravity, our brains might have evolved in a different trajectory, or our livers might not filter liquids as it does on Earth.

By recreating embryonic organ formation in space, we can anticipate how the human body in the womb would develop. There are several research initiatives going on in my lab with human brain organoids at ISS, designed to learn the impact of zero gravity on the developing human brain. These projects will have profound implications for future human colonization (can humans successfully reproduce in space?). These studies will also improve the generation of artificial organs that are used for testing drugs and treatments on Earth. Will better treatments for neurodevelopmental and neurodegenerative conditions that affects millions of people come from research in space?

More:
Why are scientists trying to manufacture organs in space? - The Conversation US

Read More...

Genomics Market 2020 Insight On The Analysis By Essential Factors And Trends In Industry By 2025 – 3rd Watch News

Friday, July 10th, 2020

Genomics Market report highlights CAGR value fluctuations during the forecast period of 2020-2025 for the market. The report presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the market. A market research analysis and estimations carried out in this Genomics report aids businesses in gaining knowledge about what is already there in the market, what market looks forward to, the competitive background and steps to be followed for outdoing the rivals. Furthermore, market research report also provides a watchful investigation of the current state of the market which covers several market dynamics.

Businesses can accomplish unparalleled and comprehensive insights along with the best acquaintance of the emerging market opportunities with this Genomics market research report. This report is structured with the meticulous efforts of innovative, enthusiastic, knowledgeable and experienced team of analysts, researchers, industry experts, and forecasters. By understanding clients requirements precisely, this report brings together business and product information for the sustainable growth in the market. Two of the major tools of market analysis employed are SWOT analysis and Porters Five Forces Analysis. The Genomics report is generated with a nice combination of advanced industry insights, practical solutions, talent solutions and the use of latest technology which gives an excellent user experience.

Get the inside scope of the Sample report @https://www.theinsightpartners.com/sample/TIPTE100000730/

MARKET INTRODUCTION

The global genomics market is expected to reach US$ 32,995.3 Mn in 2025 from US$ 14,728.6 in 2017. The market is estimated to grow with a CAGR of 10.8% from 2018-2025.

Genomics market is segmented by technology, product & services, application and end user. Global genomics market, based on technology was segmented into sequencing, microarray, PCR, nucleic acid extraction and purification, and others. Global genomics market, based on the product & services was segmented into instruments/systems, consumables, and services. The genomics market, based on application was segmented into diagnostics, drug discovery & development, precision/personalized medicine, agriculture & animal research and others. The genomics market is bifurcated on basis of end user such research centers, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users.

Key Competitors In Market are

The top 10 industry players operating in the market of genomics across the globe includes Thermo Fisher Scientific Inc., Illumina Inc., and Eurofins, Qiagen, Agilent Technologies, BGI, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Danaher, and GE Healthcare. For instance, in October 2017, MGI Tech, a subsidiary corporation of BGI, launched two new next generation genetic sequencers, MGISEQ-2000 and MGISEQ-200 in Shenzhen, China. MGI also launched a modular NGS workstation, MGIFLP along with other products. And the launch expanded the business of the company in global genomics market.

TOC of Market Report Contains:

MARKET SCOPE

The objective of the study is to describe, define, and forecast the genomics market by technology, product & services, application, end user and region. The report also provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and trends). The report helps to analyze market with respect to individual growth trends, prospects, and contributions to the overall market.

Market segmentation:

Genomics Market to 2025 Global Analysis and Forecasts by Technology (Sequencing, Microarray, PCR, Nucleic Acid Extraction and Purification, and Others), Product & Service (Instruments/Systems, Consumables, and Services), Application (Diagnostics, Drug Discovery and Development, Precision/Personalized Medicine, Agriculture & Animal Research, and Others) End User (Research Centers, Hospitals and Clinics, Pharmaceutical & Biotechnology Companies, and Others) and Geography

By Geography North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. And 13 countries globally along with current trend and opportunities prevailing in the region.

Click to buy full report with all description:https://www.theinsightpartners.com/buy/TIPTE100000730/

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

Read more:
Genomics Market 2020 Insight On The Analysis By Essential Factors And Trends In Industry By 2025 - 3rd Watch News

Read More...

Supporting Canada’s Healthcare Industry with Trusted Technology in Response to COVID-19 – Microsoft

Friday, July 10th, 2020

Post by Lisa Carroll, Canadian Public Sector Lead, Microsoft Canada

As the COVID-19 pandemic unfolded earlier this year, healthcareprovidersacross the country found themselves like so many other organizations having to urgently reinvent ways to operate, provide patient care, manage supply chains and deploy resources, with many of the usual ways of doing things suddenly off the table.With every second counting,the industryquicklyrealizedthat the immediate implementation andredeploymentof valuable resources wasanimperative.

It hasnt been easy, butamidst the crisisand uncertainty, we have continued to persevere.I amtrulyamazed at the incredibletransformationour healthcaresystemhasimplemented in such a short period of time.Healthcare providersquickly pivoted to newways of operating, while also coming together as a community todevelopnew solutionsforsafe and securetesting toprotect the health and wellbeing of our Citizens andsupporting the initiation ofthereopening our economy.

Microsoft has been working closely withpartnersand customersthroughout the pandemicto solve these big challenges by connecting health data and systems in the cloud, making health work better for patients and providers, and advancing precision medicine.Akey priority for us is providingthese organizationswith the peaceof mind to remainconfidentthattheir data is beingprocessed bytrustedMicrosoft platformsthat aresecure and compliant by designmeetingmore than70industry-widecertifications.Recognizing that thehealthcare sector is particularly vulnerable tocyber-attacksduring times of crisis, Microsofthas also recentlyimplementedanintensified monitoring and takedown ofpotentialthreatswith anemphasis on protecting critical services,such ashospitals.

I wanted to take a moment to pause and recognize the resilience and ingenuity of a smallsamplingof the many organizations who areresponding and protectingour communities across Canada:

POWERING THE HEART OF VIRTUAL CARE

POWERING INSIGHTS FOR BETTER PATIENT OUTCOMES

ACCELERATING HEALTHCARE DELIVERY

There is something to be said about hownecessityand emergencyoften drive innovation, andwe are especially proud to becollaboratingwith Citizen Care Pod Corporation,WZMH Architects, PCL Construction and Insight Enterpriseson a new initiative todeveloped with the intent torevolutionizetheaccessibilityand safety of COVID-19 testing.The Citizen Care Pod is a customizable unit outfitted with the capabilities to enable turnkey mobile COVID-19 testing in high-traffic business environments and communities with the goal to expedite testing, screening, and eventually vaccination on mass scale.

Utilizing modular construction methods, PCL Construction is manufacturing and assembling the pods by retrofitting shipping containers with customizable options to support rapid delivery and installation toany site, including high-traffic or remote locations.Eachpodis equipped with a suite of intelligent, customizable technologies powered by Microsofts trusted Azure and AI platform,which support a safe and secure testing environment for patients and front-linehealthcareworkers.

CANADIANS ARESTRONGER TOGETHER

Each passing day of this pandemic bringsnew challenges,butitsbeenincredible to see howgovernments and healthcare organizations across the countryarequickly reinventingways to operateasmany of the changes put in place today will help medical professionals deliver personalized care to Canadians in new, innovative ways in the post-COVID world.

We are proud to be part of new solutionsand new partnerships as we join together in our common cause.As the saying goes, it takes a village and at Microsoft we are committed to being there for all of our customers and partners to weather this storm together.

To learn more about Microsoft solutions that can help in the fight against COVID-19, visitaka.ms/healthcareincanada

More here:
Supporting Canada's Healthcare Industry with Trusted Technology in Response to COVID-19 - Microsoft

Read More...

Ripple Science Partners with Lakeside Life Science to Accelerate the Clinical Validation Process for Medsential’s Point-of-Care COVID-19 Antibody Test…

Friday, July 10th, 2020

Ripple Science Logo

ANN ARBOR, Mich. (PRWEB) July 09, 2020

Ripple Science today announced their partnership with Lakeside Life Science, a diagnostic research organization that is performing a clinical study to determine antibodies using Medsentials COVID-19 IgG/IGM Rapid Test Cassette. With 11.6 Million cases and over 500,000 deaths worldwide, the public health crisis that is COVID-19 has accelerated organizations to adopt technology like Ripple, which shorten time-to-market for biopharma solutions.

Ripple is a web-based platform designed for clinical research teams who want a secure and streamlined way to recruit, manage, and retain patients for trials. Ripple is a purpose-built CRM and project manager which organizes clinical trial recruiting and research efforts, leading to valuable time and cost savings. Medsentials test is already available for high-complexity CLIA certified labs. Lakesides study will be validating the test in a clinical setting. Paul Allard, COO of Lakeside Life Science, explained how Ripple helps with a very short timeline: Ripple is streamlining the whole clinical study process for us. Our timeline for this study is incredibly short. Normally we need four to six months for study start up and 18 months to enroll patients. Our goal is to complete this entire study under a month and a half.

Allard anticipates a follow-on study to determine how long a person has the antibodies. Lakeside, an expert in testing validation, has confirmed that Medsentials IgM/IgG antibody test outperform antibody tests from well-known industry healthcare providers. Allard said, In moving to a long-term study, we want high confidence in our antibody testing solution and are delighted at Medsentials results and how easy the tests are to use.

Lakeside is using Ripple to quickly recruit and track patients from small, underserved community centers that dont have access to standard testing or the tools to manage clinical studies. Patients from these small centers can benefit from access to testing and are more representative of the general population.

Clinical studies are known for their complex nature beginning with recruiting patients to continual patient engagement, especially for follow-up months after the study commences. Chiao-ih Hui, COO for Medsential, is pleased that many of the study complexities are being removed. I love that Ripple is making this highly involved and complex clinical process easier and streamlined. This will accelerate and provide a model for getting our solution to point-of-care settings and to vulnerable populations who have the most need for these solutions.

President and CEO of Ripple Science, Peter Falzon commented, With COVID-19, the way we conduct clinical trials has changed and there is a heightened sense of urgency. The team at Ripple Science is dedicated to enabling clinical research teams to work remotely and adopt virtual research methods, while boosting recruitment and retention.

About Lakeside Life Science:Lakeside Life Science was founded in January of 2015, by W. Jeffrey and Paul Allard to bring patients and communities together to advance personalized medicine through the research and development of novel diagnostic tests. Lakeside provides the resources for their clients to bring their assays from invention to FDA clearance/approval, while putting patient needs first.

About Medsential: Medsential LLC is a US FDA registered company that develops, manufactures, and distributes a broad range of medical products to customers. Established in 2005, Medsential is an ISO certified medical device company with the capabilities to manufacture and assemble a broad range of products. Medsential has an extensive distribution channel, salesforce, engineering platform, and production team to bring quality products to global markets.

About Ripple Science: Ripple Science accelerates clinical research with its secure, HIPAA-compliant suite of tools. By adapting sales and marketing automation to the process of patient recruitment, Ripple helps our customers recruit more participants, faster and reduces patients lost to follow-up. Ripple Sciences flagship product, Ripple, is currently being used by research investigators at more than 100 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia (UK), Cognito Therapeutics (Boston, MA) and the University of Michigan.

To learn more, please visit: https://www.ripplescience.com

Share article on social media or email:

Read more:
Ripple Science Partners with Lakeside Life Science to Accelerate the Clinical Validation Process for Medsential's Point-of-Care COVID-19 Antibody Test...

Read More...

Global Digital Genome Market and COVID-19 Impact Assessment 2019-2027 – A $20+ Billion Industry Opportunity with Lucrative Growth Projected for…

Friday, July 3rd, 2020

Dublin, July 03, 2020 (GLOBE NEWSWIRE) -- The "Global Digital Genome Market Forecast to 2027 - COVID-19 Impact and Analysis by Product, Application, End-user, Geography and Company" report has been added to ResearchAndMarkets.com's offering.

The global digital genome market was valued at US$ 11,065.31 million in 2019 and is projected to reach US$ 20,812.81 million by 2027; it is expected to grow at a CAGR of 8.4% during 2020-2027.

The growth of the digital genome market is mainly attributed to factors such as the increasing prevalence of chronic diseases and growing funding for genomics. However, dearth of skilled professionals is likely to restraint the growth of the market during the forecast years.

Genomic sequencing is rapidly transitioning into clinical practice, and implementation into healthcare systems has been supported by substantial government investment, accounting for US$ 4 billion in at least 14 countries. These national genomic medicine initiatives are driving transformative change under real-life conditions while simultaneously addressing barriers to implement and gather evidence for broader adoption.

The UK has announced the world's largest genome project as part of 200 million public-private collaboration between charities and pharmaceutical. The UK has already developed the largest genome database in the world through the 100,000 Genomes Project. Led by Innovate UK as part of UK Research and Innovation, the project will fund researchers and industry to combine data and real-world evidence from UK health services and create new products and services that diagnose diseases efficiently.

Moreover, in August 2018, Boston, a Massachusetts-based company, announced that it landed US$ 4.3 million in seed funding and that it would be partnering with Veritas Genetics, a genome sequencing company. The funds will support the company's mission to usher in the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data.

Cardiovascular diseases (CVDs) such as atherosclerosis, angina pectoris, and acute myocardial infarction are a significant cause for mortality in the world owing to the present day hectic lifestyle. As per the data provided by WHO, CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Diabetes is one of the life-threatening chronic diseases with no functional cure. Diabetes of all types can lead to various complications in different parts of the body and can increase the overall risk of premature death.

Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. As there is a significant increase in diabetes cases across the world, it results in life-changing complications among the population. According to the International Diabetes Federation (IDF), in 2017, 46 million diabetic patients were reported in North America, which is expected to reach 62 million in 2045. As chronic diseases are increasing at a faster pace, the research on genomics for life-threatening illnesses has progressed rapidly over the last five years, thereby driving the market growth during the forecast period.

Based on product, the digital genome market is segmented into DNA/RNA analysis, sequencing chips, sequencing and analyzer instruments, sample prep instruments, and sequencing and analysis software. The sequencing and analyzer instruments segment held the largest share of the market in 2019; whereas, the sequencing chips segment is estimated to register the highest CAGR in the market during the forecast period.

Based on application, the digital genome market is segmented into diagnostics, agricultural, academic research, drug discovery, personalized medicine, and other applications. The diagnostics segment held the largest share of the market in 2019; however, personalized medicine segment is estimated to register the highest CAGR in the market during the forecast period.

Based on end-user, the global digital genome market is segmented into diagnostics and forensic labs, academic research institutes, hospitals, and others. The diagnostics and forensic labs segment held the highest share of the market in 2019; whereas, the academic research institutes segment is estimated to register the highest CAGR in the market during the forecast period.

Key Topics Covered

1. Introduction1.1 Scope of the Study1.2 Report Guidance1.3 Market Segmentation1.3.1 Global Digital Genome Market - By Product1.3.2 Global Digital Genome Market - By Application1.3.3 Global Digital Genome Market - By End-user1.3.4 Global Digital Genome Market - By Geography

2. Digital Genome Market - Key Takeaways

3. Research Methodology3.1 Coverage3.2 Secondary Research3.3 Primary Research

4. Global Digital Genome Market - Market Landscape4.1 PEST Analysis4.1.1 North America - PEST Analysis4.1.2 Europe - PEST Analysis4.1.3 Asia-Pacific - PEST Analysis4.1.4 Middle East and Africa - PEST Analysis4.1.5 South and Central America - PEST Analysis4.2 Expert Opinion

5. Digital Genome Market - Key Market Dynamics5.1 Market Drivers5.1.1 Growing Funding for Genomics5.1.2 Increasing Prevalence of Chronic Diseases5.2 Market Restraints5.2.1 Dearth of Skilled Professionals5.3 Market Opportunities5.3.1 Increasing Technological Advancement in Digital Genome Field5.4 Future Trends5.4.1 Increasing Demand for Personalized Medicines5.5 Impact analysis

6. Digital Genome Market - Global Analysis6.1 Global Digital Genome Market Revenue Forecast and Analysis6.2 Global Digital Genome Market, By Geography - Forecast and Analysis6.3 Market Positioning of Key Players

7. Digital Genome Market Analysis - By Product7.1 Overview7.2 Digital Genome Market Revenue Share, by Product (2019 and 2027)7.3 DNA/RNA Analysis7.4 Sequencing and Analyzer Instruments7.5 Sequencing and Analysis Software7.6 Sequencing Chips7.7 Sample Prep Instruments

8. Digital Genome Market - By Application8.1 Overview8.2 Digital Genome Market, by Application, 2019 and 2027 (%)8.3 Diagnostics8.4 Drug Discovery8.5 Academic Research8.6 Personalized Medicine8.7 Agricultural8.8 Others

9. Digital Genome Market - By End-user9.1 Overview9.2 Digital Genome Market, by End-user, 2019 and 2027 (%)9.3 Diagnostics & Forensic Labs9.5 Academic Research Institutes9.6 Hospitals9.7 Other End-users

10. Digital Genome Market - Geographic Analysis10.1 North America: Digital Genome Market10.2 Europe: Digital Genome Market10.3 Asia-Pacific: Digital Genome Market10.4 Middle East & Africa: Digital Genome Market10.5 South and Central America: Digital Genome Market

11. Impact of COVID-19 Pandemic on Global Digital Genome Market11.1 North America: Impact Assessment of COVID-19 Pandemic11.2 Europe: Impact Assessment of COVID-19 Pandemic11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Digital Genome Market - Industry Landscape12.1 Overview12.2 Growth Strategies Done by the Companies in the Market, (%)12.3 Organic Developments12.4 Inorganic Developments

13. Company Profiles13.1 Thermo Fisher Scientific Inc.13.2 F. Hoffmann-La Roche Ltd.13.3 Illumina, Inc.13.4 QIAGEN13.5 GenomeMe13.6 NanoString Technologies, Inc.13.7 BD13.8 bioMerieux SA13.9 GenMark Diagnostics, Inc.13.10 Perkin Elmer, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/bi9red

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the original post:
Global Digital Genome Market and COVID-19 Impact Assessment 2019-2027 - A $20+ Billion Industry Opportunity with Lucrative Growth Projected for...

Read More...

Page 20«..10..19202122..3040..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick